Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Journal of Pharmacology

• Publication date

  2006-11-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EJPHAR.2006.08.016PMID 16978602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plexogenic arteriopathy

  2016influential reference
• Treatment of pulmonary arterial hypertension.

  2006influential reference
• The role of increased pulmonary blood flow in pulmonary arterial hypertension

  2005cited by this paper
• Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.

  2005cited by this paper
• Treatment of pulmonary arterial hypertension.

  2004cited by this paper
• Differential regulation of glomerular and interstitial endothelial nitric oxide synthase expression in the kidney of hibernating ground squirrel.

  2004cited by this paper
• Prostacyclin Induces Apoptosis of Vascular Smooth Muscle Cells by a cAMP-Mediated Inhibition of Extracellular Signal-Regulated Kinase Activity and Can Counteract the Mitogenic Activity of Endothelin-1 or Basic Fibroblast Growth Factor

  2004cited by this paper
• Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat.

  2004cited by this paper
• Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension

  2004cited by this paper
• Pathologic assessment of vasculopathies in pulmonary hypertension.

  2004influential reference
• Intravascular Thrombosis After Hypoxia-Induced Pulmonary Hypertension: Regulation by Cyclooxygenase-2

  2004cited by this paper
• Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts.

  2004cited by this paper
• Angiogenic effect of prostaglandin I 2 in relation with its effect on PPAR nuclear receptors.

  2004cited by this paper
• Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors.

  2004cited by this paper
• Progressive development of pulmonary hypertension leading to right ventricular hypertrophy assessed by echocardiography in rats.

  2003cited by this paper
• The prostaglandins epoprostenol and iloprost increase left ventricular contractility in vivo

  2003cited by this paper
• Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression.

  2003cited by this paper
• Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension?

  2002cited by this paper
• Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension.

  2002cited by this paper
• Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.

  2002cited by this paper
• Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease.

  2002cited by this paper
• Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.

  2001cited by this paper
• Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy.

  2001cited by this paper
• Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension.

  2001cited by this paper
• A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION

  2000cited by this paper
• Inhibition of Endothelial Cell Migration, Intercellular Communication, and Vascular Tube Formation by Thromboxane A2 *

  1999cited by this paper
• Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta.

  1999cited by this paper
• Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.

  1999cited by this paper
• The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

  1999influential reference
• Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

  1998cited by this paper
• Experimental fat embolism induces urine 2,3-dinor-6-ketoprostaglandin F1alpha and 11-dehydrothromboxane B2 excretion in pigs.

  1997cited by this paper
• Experimental fat embolism induces urine 2,3-dinor-6-ketoprostaglandin F sub 1 alpha and 11-dehydrothromboxane B sub 2 excretion in pigs

  1997cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996influential reference
• Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat.

  1995cited by this paper
• Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin

  1994cited by this paper
• Eicosanoids: Critical Agents in the Physiological Process and Cellular Injury

  1993cited by this paper
• Eicosanoid levels in bronchoalveolar lavage fluid of young female smokers and non‐smokers

  1992cited by this paper
• An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

  1992cited by this paper
• Effects of prostacyclin analogue, OP-2507, on function and metabolism in the ischemic working rat heart

  1992cited by this paper
• Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

  1990cited by this paper
• Morphometry of the small arteries and arterioles in the rat heart: effects of chronic hypertension and exercise.

  1990cited by this paper
• Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial

  1990influential reference
• Biopsy Pathology of the Pulmonary Vasculature

  1990influential reference
• Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension.

  1989cited by this paper
• Strain differences in pulmonary hypertensive response to monocrotaline alkaloid and the beneficial effect of oral magnesium treatment.

  1989cited by this paper
• Low-dose PGI2 prevents monocrotaline-induced thromboxane production and lung injury.

  1986cited by this paper
• Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension.

  1985cited by this paper
• Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).

  1984cited by this paper
• Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.

  1983cited by this paper
• Inhibition of endogenous thromboxane synthesis by exogenous prostacyclin during endotoxemia in conscious sheep.

  1982cited by this paper
• Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

  1982cited by this paper
• Inhibition of endogenous thromboxane synthesis by exogenous prostacyclin during endotoxemia in conscious sheep.

  1982cited by this paper
• Lung biopsy specimens in the evaluation of pulmonary vascular disease.

  1980influential reference
• Regional capillary supply in the normal and hypertrophied rat heart.

  1980cited by this paper
• Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features.

  1979cited by this paper
• LIVER IN REGULATION OF FIBRINOLYTIC ACTIVITY.

  1964cited by this paper

• Microvascular preservation & cardiomyocyte hyperplasia underlie adaptive right ventricle development in congenital heart disease-pulmonary arterial hypertension.

  2025cites this paper
• Angiogenesis Induction as a Key Step in Cardiac Tissue Regeneration: From Angiogenic agents to Biomaterials.

  2023cites this paper
• New insights into the pathobiological and pharmacological basis of the sex-disparity in patients with pulmonary arterial hypertension.

  2021cites this paper
• Animal Models of PAH and Increased Pulmonary Blood Flow

  2021cites this paper
• CYLD mediates human pulmonary artery smooth muscle cell dysfunction in congenital heart disease‐associated pulmonary arterial hypertension

  2021cites this paper
• Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism.

  2020cites this paper
• Right ventricular phenotype, function, and failure: a journey from evolution to clinics

  2020cites this paper
• Nestin represents a potential marker of pulmonary vascular remodeling in pulmonary arterial hypertension associated with congenital heart disease.

  2020cites this paper
• Right ventricular pressure overload alters cardiac lipid composition.

  2019cites this paper
• New Pharmacologic Therapy for Hypertension in Pregnancy

  2019cites this paper
• Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure

  2019influential citation
• The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension

  2018cites this paper
• Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

  2018cites this paper
• Trimedazidine alleviates pulmonary artery banding-induced acute right heart dysfunction and activates PRAS40 in rats

  2017cites this paper
• Inhibition of MLCK attenuates pulmonary artery hypertension

  2016cites this paper
• Effects of chronic treprostinil treatment on experimental right heart hypertrophy and failure

  2016cites this paper
• Animal Models of Pulmonary Hypertension

  2016cites this paper
• Treatment of Chronic Right Heart Failure

  2015cites this paper
• A "cure" for preeclampsia: Improving neonatal outcomes by overcoming excess fetal placental vascular resistance.

  2015cites this paper
• Advancing knowledge of right ventricular pathophysiology in chronic pressure overload: Insights from experimental studies.

  2015cites this paper
• The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors.

  2015cites this paper
• Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement?

  2015influential citation
• Treatment for pulmonary arterial hypertension-associated right ventricular dysfunction.

  2014cites this paper
• Right Ventricular Adaptation in Congenital Heart Diseases

  2014cites this paper
• Animal Models for PAH and Increased Pulmonary Blood Flow

  2014cites this paper
• Assessment of right ventricular responses to therapy in pulmonary hypertension.

  2014cites this paper
• The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models.

  2013cites this paper
• Experimental Models of Right Heart Failure: A Window for Translational Research in Pulmonary Hypertension

  2013cites this paper
• of Pulmonary Arterial Hypertension

  2013cites this paper
• Retentissement musculaire cardiaque et périphérique de l'hypertension artérielle pulmonaire induite par la monocrotaline chez le rat : dysfonction mitochondriale et effet de l'exercice excentrique

  2012cites this paper
• Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension

  2012cites this paper
• Paediatric pulmonary hypertension: epidemiology, characterisation and treatment

  2010cites this paper
• Gene expression profile in flow-associated pulmonary arterial hypertension with neointimal lesions.

  2010influential citation
• Novel Approaches to Treat Experimental Pulmonary Arterial Hypertension: A Review

  2010cites this paper
• Galphaq-protein carboxyl terminus imitation polypeptide (GCIP)-27 inhibits right ventricular hypertrophy induced by monocrotaline in rats.

  2009cites this paper
• Novel approaches to treat pulmonary arterial hypertension

  2009cites this paper
• Molecular and cellular characterization of cardiac overload-induced hypertrophy and failure

  2009cites this paper
• Peroxisome Proliferator-Activated Receptor Alpha Is Crucial for Iloprost-Induced in vivo Angiogenesis and Vascular Endothelial Growth Factor Upregulation

  2008cites this paper